SAN DIEGO, CA, USA I August 19, 2015 I SignalRx Pharmaceuticals Inc., focused on developing more effective oncology drugs through molecular design imparting selective multiple target inhibition, today announced that the first pediatric cancer patient has been dosed with the “first-in-pediatric-class” PI-3 kinase (PI3K) inhibitor SF1126. This represents a breakthrough for our strategy to leverage the novel anticancer agent SF1126, successfully evaluated in adult Phase I clinical trials, into helping children with cancer in an area of great unmet need: pediatric cancer treatment.
SF1126 is the first drug of its kind used to treat a child with cancer. The drug has been reported to have no dose limiting toxicity in adult cancer patient trials and was well tolerated with significant clinical benefit. The first pediatric patient to receive SF1126 was previously diagnosed with neuroblastoma and showed no side effects after their first treatment with SF1126. This agent holds a great potential to have a significant impact on the treatment of pediatric cancers in the future. We are excited to report this new pediatric cancer development in the clinic and the promise SF1126 brings to help kids with cancer.
The clinical evaluation of SF1126 in pediatric patients with neuroblastoma is being performed as part of the New Approaches to Neuroblastoma Therapy Consortium (NANT) Study, funded by the St. Balderick’s Foundation and the National Institutes of Health (NIH). SF1126 is a “first-in-pediatric class” targeted anticancer therapeutic agent being developed by SignalRx in collaboration with Donald L. Durden, MD PhD, at the UCSD/Moores Cancer Center and Rady Children’s Hospital.
SF1126 was designed to inhibit PI3K, a proven central nodal element in cancer cells. SF1126 has a unique inhibition profile that also includes the inhibition of the epigenetic reader bromodomain protein BRD4, a protein responsible for the transcription of the oncogene MYC. Since PI3K inhibition has also been shown to enhance degradation of MYC, our dual PI3K/BRD4 inhibitor SF1126 represents a unique approach in cancer treatment to block multiple synergistic pathways important to many cancers. “By benefit of this dual inhibition maximally blocking MYC, SF1126 may be most effective in patients whose cancers are highly dependent on cMYC or MYCN such as in certain neuroblastoma patients. SignalRx Pharmaceuticals is dedicated to bringing new dual targeted therapies, like SF1126, into pediatric oncology trials” said Dr. Durden.
About SignalRx Pharmaceuticals Inc.
SignalRx is a privately held corporation based in San Diego, California developing novel small molecule inhibitors against multiple, carefully selected key signaling pathways used by cancer and cancer stem cells to evade current anticancer therapeutics. The company pursues the simultaneous blockage of key signaling pathways playing major roles in cell survival mechanisms, epigenetic regulation processes, and DNA repair actions encompassing critical cancer targets, such as PI3K, MEK, BRAF, Wnt, HDAC, DNMT, PARP and BET bromodomains. SignalRx is leveraging its expertise in selective cancer pathway inhibition to be the leader in developing single molecule therapeutics that selectively inhibit synergistic critical cancer pathways. These selectively designed multi-action therapeutics are expected to be cost-effective and exhibit enhanced anticancer effects.
SOURCE: SignalRx Pharmaceuticals
Post Views: 124
SAN DIEGO, CA, USA I August 19, 2015 I SignalRx Pharmaceuticals Inc., focused on developing more effective oncology drugs through molecular design imparting selective multiple target inhibition, today announced that the first pediatric cancer patient has been dosed with the “first-in-pediatric-class” PI-3 kinase (PI3K) inhibitor SF1126. This represents a breakthrough for our strategy to leverage the novel anticancer agent SF1126, successfully evaluated in adult Phase I clinical trials, into helping children with cancer in an area of great unmet need: pediatric cancer treatment.
SF1126 is the first drug of its kind used to treat a child with cancer. The drug has been reported to have no dose limiting toxicity in adult cancer patient trials and was well tolerated with significant clinical benefit. The first pediatric patient to receive SF1126 was previously diagnosed with neuroblastoma and showed no side effects after their first treatment with SF1126. This agent holds a great potential to have a significant impact on the treatment of pediatric cancers in the future. We are excited to report this new pediatric cancer development in the clinic and the promise SF1126 brings to help kids with cancer.
The clinical evaluation of SF1126 in pediatric patients with neuroblastoma is being performed as part of the New Approaches to Neuroblastoma Therapy Consortium (NANT) Study, funded by the St. Balderick’s Foundation and the National Institutes of Health (NIH). SF1126 is a “first-in-pediatric class” targeted anticancer therapeutic agent being developed by SignalRx in collaboration with Donald L. Durden, MD PhD, at the UCSD/Moores Cancer Center and Rady Children’s Hospital.
SF1126 was designed to inhibit PI3K, a proven central nodal element in cancer cells. SF1126 has a unique inhibition profile that also includes the inhibition of the epigenetic reader bromodomain protein BRD4, a protein responsible for the transcription of the oncogene MYC. Since PI3K inhibition has also been shown to enhance degradation of MYC, our dual PI3K/BRD4 inhibitor SF1126 represents a unique approach in cancer treatment to block multiple synergistic pathways important to many cancers. “By benefit of this dual inhibition maximally blocking MYC, SF1126 may be most effective in patients whose cancers are highly dependent on cMYC or MYCN such as in certain neuroblastoma patients. SignalRx Pharmaceuticals is dedicated to bringing new dual targeted therapies, like SF1126, into pediatric oncology trials” said Dr. Durden.
About SignalRx Pharmaceuticals Inc.
SignalRx is a privately held corporation based in San Diego, California developing novel small molecule inhibitors against multiple, carefully selected key signaling pathways used by cancer and cancer stem cells to evade current anticancer therapeutics. The company pursues the simultaneous blockage of key signaling pathways playing major roles in cell survival mechanisms, epigenetic regulation processes, and DNA repair actions encompassing critical cancer targets, such as PI3K, MEK, BRAF, Wnt, HDAC, DNMT, PARP and BET bromodomains. SignalRx is leveraging its expertise in selective cancer pathway inhibition to be the leader in developing single molecule therapeutics that selectively inhibit synergistic critical cancer pathways. These selectively designed multi-action therapeutics are expected to be cost-effective and exhibit enhanced anticancer effects.
SOURCE: SignalRx Pharmaceuticals
Post Views: 124
